Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Tagawa on Updated Results of TAXYNERGY Trial in Prostate Cancer

February 23rd 2017

Scott T. Tagawa, MD, Weill Cornell Medicine, discusses the updated results of a prospective biomarker anaylsis from the TAXYNERGY trial in patients with metastatic castration-resistant prostate cancer (mCRPC).

Dr. Saad on Apalutamide Combination for Castration-Resistant Prostate Cancer

February 23rd 2017

Fred Saad, MD, University of Montreal Hospital Centers, discusses the safety and efficacy of the apalutamide combination for patients with metastatic castration-resistant prostate cancer.

Dr. Morris on Challenges of Radium-223 Treatment in Prostate Cancer

February 23rd 2017

Michael J. Morris, MD, Memorial Sloan Kettering Cancer Center, discusses the challenges associated with radium-223 treatment in prostate cancer.

Dr. Oh Discusses the Role of Chemotherapy in Prostate Cancer

February 22nd 2017

William K. Oh, MD, professor, Mount Sinai Hospital, discusses the current role of chemotherapy in the treatment of patients with prostate cancer.

Dr. Saad on Radium-223 for Prostate Cancer

February 22nd 2017

Fred Saad, MD, professor and chief of Urology, Director of Genitourinary Oncology at the University of Montreal Hospital Centers, discusses radium-223 dichloride (Xofigo) for patients with prostate cancer.

Josh Armenia on Impact of Mutated Gene Analysis in Prostate Cancer

February 22nd 2017

Josh Armenia, PhD, Memorial Sloan Kettering Cancer Center, discusses the impact of a gene mutation analysis study in prostate cancer.

Lancaster Urology Brings Clinical Trials to Community Setting

February 21st 2017

Lancaster Urology, one of the largest urology practices in western Pennsylvania, fills the geographic void between Pittsburgh and Philadelphia by providing the whole spectrum of urologic care.

Dr. Saad on Recent Updates in Active Surveillance in Prostate Cancer

February 20th 2017

Fred Saad, MD, professor and chairman of Urology, director of Genitourinary Oncology, the University of Montreal Hospital Centers, discusses recent updates in active surveillance for patients with prostate cancer.

Genomic Test Predicts Metastasis, Mortality in Prostate Cancer

February 18th 2017

The genomic-based Decipher test effectively predicted metastasis and prostate cancer-specific mortality from diagnostic biopsy specimens for patients with intermediate- and high-risk prostate cancer.

Dr. Spratt on Combination of Immunotherapy and Radiation in Prostate Cancer

February 18th 2017

Daniel Eidelberg Spratt, MD, assistant professor, radiation oncology, University of Michigan Health System, discusses the combination of immunotherapy and radiation in patients with prostate cancer.

Olaparib, Durvalumab Combo Active in Prostate Cancer

February 17th 2017

According to preliminary results from an ongoing trial, half of a small group of patients with metastatic castration-resistant prostate cancer had a PSA response during treatment with the PD-L1 inhibitor durvalumab and the PARP inhibitor olaparib (Lynparza).

AR-FL mRNA Correlates With Response to AR-Targeted Therapies

February 17th 2017

According to results of a prospective clinical study, circulating tumor cell mRNA of full-length androgen receptor (AR) correlated with detection of the AR-V7 variant and with response to AR-targeted therapy for castration-resistant prostate cancer.

Dr. Oh on Results of Chemotherapy Versus ARTA in Prostate Cancer

February 17th 2017

William Oh, MD, professor, Mount Sinai Hospital, discusses the results from a trial that compared second-line chemotherapy to alternative androgen receptor-targeted agents (ARTA) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Josh Armenia on Results of Mutated Gene Analysis in Prostate Cancer

February 17th 2017

Josh Armenia, PhD, Memorial Sloan Kettering Cancer Center, discusses the results of an analysis of significantly mutated genes in prostate cancer.

Dr. Dreicer on Future Treatment Approaches in Prostate Cancer

February 17th 2017

Robert Dreicer, MD, associate director for Clinical Research and deputy director of the University of Virginia Cancer Center, discusses the progress he would like to see accomplished in the field of metastatic castration-resistant prostate cancer.

Phase III Results Support Novel Focal Therapy for Low-Risk Prostate Cancer

February 16th 2017

Padeliporfin vascular-targeted photodynamic therapy, a novel tissue-preserving treatment, may offer men with low-risk prostate cancer a safe and effective alternative to either active surveillance or radical therapy, according to the results of a phase III trial.

Dr. Buffington on MRI Fusion for Prostate Cancer

February 15th 2017

Philip J. Buffington, MD, chief medical officer, The Urology Group, discusses MRI fusion-guided biopsy in patients with prostate cancer.

Circulating Tumor DNA Can Advance Personalized Care in mCRPC

February 14th 2017

Up to 94% of patients with metastatic castration-resistant prostate cancer have circulating tumor DNA with at least 1 genetic alteration, suggesting ctDNA could be a noninvasive alternative to traditional tumor biopsies and help personalize treatment in this setting.

Dr. Albala on Patient Selection for Robotic Surgery in Prostate Cancer

February 9th 2017

David Albala, MD, urologist and medical director, Associated Medical Professionals, discusses patients with prostate cancer who are best suited to be treated with robotic surgery.

Dr. Scher on Promise of Liquid Biopsies in Prostate Cancer

February 8th 2017

Howard I. Scher, MD, chief, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the potential that liquid biopsies will have in the treatment landscape of prostate cancer.